|Sandra S. Park, JD|
A recording is now available of the special breaking-science symposium added to the 2013 AACC meeting—a joint session with the Association for Molecular Pathology (AMP)—offering an industry perspective on the implications for lab practice and patient care of the recent Supreme Court ruling that isolated human DNA cannot be patented.
Barbara Zehnbauer, PhD, medical director, Molecular Diagnostics Laboratory at the Washington University School of Medicine, serves as moderator. The speakers are Sandra S. Park, JD, senior staff attorney, American Civil Liberties Union (ACLU) Women’s Rights Project, and Federico Monzon, MD, director of Molecular Pathology, Cancer Genetics Laboratory, Baylor University, Houston.
|Federico Monzon, MD|
Park was the lead counsel in the lawsuit challenging patents held by Myriad Genetics for the BRCA1 and BRCA2 genes, which led to the Supreme Court’s landmark ruling.
She discusses the case, the decision, and immediate reaction.
Monzon offers insights on the impact of the Supreme Court’s decision on the practice of molecular diagnostics and genetic testing, not limited to to BRCA 1 and BRCA 2 genes.
AACC’s 2013 Annual Meeting recordings are available to purchase; visit the AACC website for more information.